We found that: a) G3139 reduced Bcl-2 expression in A375 tumors but had no significant effect in different non-tumor tissues (including liver, brain, lung, heart, kidney, or skeletal muscle; although, as an example, only data for the liver are shown); b) G3622 (reversed sequence), as compared to physiological saline-treated controls, does not deplete significantly Bcl-2 neither in the tumor nor in non-tumor tissues (see Additional file 1 Figure S1B). The gene discussed is BCL2; the disease is neoplasm.